HF
TLX

HRT Financial’s Telix Pharmaceuticals TLX Stock Holding History

HRT Financial’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$295K Buy
+25,637
New +$261K ﹤0.01% 3088
2025
Q4 		– Sell
-11,641
Closed -$111K – 4261
2025
Q3 		$111K Buy
+11,641
New +$143K ﹤0.01% 2509

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $358M AUM 26.37% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $15.3B AUM 25.33% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

HRT Financial's TLX Position: Q2 2026 in Review

HRT Financial opened a new position in Telix Pharmaceuticals (TLX) in Q2 2026: 25,637 shares worth $295K. The stake represents ﹤0.01% of the portfolio and ranks #3088 among its holdings. This is a return to the name: HRT Financial previously reported a position in TLX as recently as Q3 2025.

HRT Financial first reported a position in TLX in Q3 2025 and has held it in 2 quarters since. 61 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • HRT Financial held 25,637 shares of Telix Pharmaceuticals worth $295K as of Q2 2026.
  • Telix Pharmaceuticals was a new HRT Financial position in Q2 2026.
  • Telix Pharmaceuticals made up ﹤0.01% of HRT Financial's portfolio in Q2 2026, its #3088 holding.
  • HRT Financial first reported a position in Telix Pharmaceuticals in Q3 2025 and has held it in 2 quarters since.
  • 61 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.